               SEQUENCE LISTING

<110> Celyad S.A.

<120> CAR T-cells targeting BCMA and uses thereof

<130> P50848WO/DJC/JG

<160> 17

<170> BiSSAP 1.3.6

<210> 1
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain CDR1

<400> 1
Ser Gly Ser Tyr Phe Trp Gly 
1               5           

<210> 2
<211> 16
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain CDR2

<400> 2
Ser Ile Tyr Tyr Ser Gly Ile Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      



<210> 3
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain CDR3

<400> 3
His Asp Gly Ala Val Ala Gly Leu Phe Asp Tyr 
1               5                   10      

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain light chain CDR1

<400> 4
Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His 
1               5                   10      

<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain light chain CDR2

<400> 5
Asp Asp Ser Asp Arg Pro Ser 
1               5           

<210> 6
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain light chain CDR3

<400> 6
Gln Val Trp Asp Ser Ser Ser Asp His Val Val 
1               5                   10      

<210> 7
<211> 121
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain

<400> 7
Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Glu 
1               5                   10                  15      
Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser Gly 
            20                  25                  30          
Ser Tyr Phe Trp Gly Trp Ile Arg Gln Pro Pro Gly Lys Gly Leu Glu 
        35                  40                  45              
Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ile Thr Tyr Tyr Asn Pro Ser 
    50                  55                  60                  
Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe 
65                  70                  75                  80  
Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 
                85                  90                  95      
Cys Ala Arg His Asp Gly Ala Val Ala Gly Leu Phe Asp Tyr Trp Gly 
            100                 105                 110         
Gln Gly Thr Leu Val Thr Val Ser Ser 
        115                 120     

<210> 8
<211> 108
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain light chain

<400> 8
Ser Tyr Val Leu Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln 
1               5                   10                  15      
Thr Ala Arg Ile Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val 
            20                  25                  30          
His Trp Tyr Gln Gln Pro Pro Gly Gln Ala Pro Val Val Val Val Tyr 
        35                  40                  45              
Asp Asp Ser Asp Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser 
    50                  55                  60                  
Asn Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly 
65                  70                  75                  80  
Asp Glu Ala Val Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His 
                85                  90                  95      
Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu 
            100                 105             

<210> 9
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain CDR1

<400> 9
Ser Ser Ser Tyr Phe Trp Gly 
1               5           

<210> 10
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain CDR1

<400> 10
Ser Gly Ser Tyr Tyr Trp Gly 
1               5           

<210> 11
<211> 7
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain CDR1

<400> 11
Ser Ser Ser Tyr Tyr Trp Gly 
1               5           

<210> 12
<211> 16
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain CDR2

<400> 12
Ser Ile Tyr Tyr Ser Gly Ser Thr Tyr Tyr Asn Pro Ser Leu Lys Ser 
1               5                   10                  15      

<210> 13
<211> 11
<212> PRT
<213> Artificial Sequence


<220> 
<223> Anti-BCMA binding domain heavy chain CDR3

<400> 13
His Asp Gly Ala Thr Ala Gly Leu Phe Asp Tyr 
1               5                   10      

<210> 14
<211> 266
<212> PRT
<213> Artificial Sequence


<220> 
<223> scFv #11

<400> 14
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 
1               5                   10                  15      
His Ala Ala Arg Pro Gln Leu Gln Leu Gln Glu Ser Gly Pro Gly Leu 
            20                  25                  30          
Val Lys Pro Ser Glu Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly 
        35                  40                  45              
Ser Ile Ser Ser Gly Ser Tyr Phe Trp Gly Trp Ile Arg Gln Pro Pro 
    50                  55                  60                  
Gly Lys Gly Leu Glu Trp Ile Gly Ser Ile Tyr Tyr Ser Gly Ile Thr 
65                  70                  75                  80  
Tyr Tyr Asn Pro Ser Leu Lys Ser Arg Val Thr Ile Ser Val Asp Thr 
                85                  90                  95      
Ser Lys Asn Gln Phe Ser Leu Lys Leu Ser Ser Val Thr Ala Ala Asp 
            100                 105                 110         
Thr Ala Val Tyr Tyr Cys Ala Arg His Asp Gly Ala Val Ala Gly Leu 
        115                 120                 125             
Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly 
    130                 135                 140                 
Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Tyr Val Leu 
145                 150                 155                 160 
Thr Gln Pro Pro Ser Val Ser Val Ala Pro Gly Gln Thr Ala Arg Ile 
                165                 170                 175     
Thr Cys Gly Gly Asn Asn Ile Gly Ser Lys Ser Val His Trp Tyr Gln 
            180                 185                 190         
Gln Pro Pro Gly Gln Ala Pro Val Val Val Val Tyr Asp Asp Ser Asp 
        195                 200                 205             
Arg Pro Ser Gly Ile Pro Glu Arg Phe Ser Gly Ser Asn Ser Gly Asn 
    210                 215                 220                 
Thr Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Val 
225                 230                 235                 240 
Tyr Tyr Cys Gln Val Trp Asp Ser Ser Ser Asp His Val Val Phe Gly 
                245                 250                 255     
Gly Gly Thr Lys Leu Thr Val Leu Ser Ser 
            260                 265     

<210> 15
<211> 295
<212> PRT
<213> Artificial Sequence


<220> 
<223> scFv #4

<400> 15
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu 
1               5                   10                  15      
His Ala Ala Arg Pro Gln Val Lys Leu Glu Glu Ser Gly Gly Gly Leu 
            20                  25                  30          
Val Gln Ala Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Glu His 
        35                  40                  45              
Thr Phe Ser Ser His Val Met Gly Trp Phe Arg Gln Ala Pro Gly Lys 
    50                  55                  60                  
Glu Arg Glu Ser Val Ala Val Ile Gly Trp Arg Asp Ile Ser Thr Ser 
65                  70                  75                  80  
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 
                85                  90                  95      
Lys Lys Thr Leu Tyr Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr 
            100                 105                 110         
Ala Val Tyr Tyr Cys Ala Ala Arg Arg Ile Asp Ala Ala Asp Phe Asp 
        115                 120                 125             
Ser Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Gly Gly Gly Gly 
    130                 135                 140                 
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser 
145                 150                 155                 160 
Gly Gly Gly Gly Ser Ala Val Gln Leu Val Glu Ser Gly Gly Gly Leu 
                165                 170                 175     
Val Gln Ala Gly Asp Ser Leu Arg Leu Thr Cys Thr Ala Ser Gly Arg 
            180                 185                 190         
Ala Phe Ser Thr Tyr Phe Met Ala Trp Phe Arg Gln Ala Pro Gly Lys 
        195                 200                 205             
Glu Arg Glu Phe Val Ala Gly Ile Ala Trp Ser Gly Gly Ser Thr Ala 
    210                 215                 220                 
Tyr Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala 
225                 230                 235                 240 
Lys Asn Thr Val Tyr Leu Gln Met Asn Ser Leu Lys Ser Glu Asp Thr 
                245                 250                 255     
Ala Val Tyr Tyr Cys Ala Ser Arg Gly Ile Glu Val Glu Glu Phe Gly 
            260                 265                 270         
Ala Trp Gly Gln Gly Thr Gln Val Thr Val Ser Ser Thr Ser Thr Thr 
        275                 280                 285             
Thr Pro Ala Pro Arg Pro Pro 
    290                 295 

<210> 16
<211> 127
<212> PRT
<213> Artificial Sequence


<220> 
<223> CD8 domain 

<400> 16
Ala Ala Ala Phe Val Pro Val Phe Leu Pro Ala Lys Pro Thr Thr Thr 
1               5                   10                  15      
Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr Ile Ala Ser Gln Pro 
            20                  25                  30          
Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala Ala Gly Gly Ala Val 
        35                  40                  45              
His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile Tyr Ile Trp Ala Pro 
    50                  55                  60                  
Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser Leu Val Ile Thr Leu 
65                  70                  75                  80  
Tyr Cys Asn His Arg Asn Lys Arg Gly Arg Lys Lys Leu Leu Tyr Ile 
                85                  90                  95      
Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu Asp 
            100                 105                 110         
Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu 
        115                 120                 125         

<210> 17
<211> 114
<212> PRT
<213> Artificial Sequence


<220> 
<223> CD3-zeta domain 

<400> 17
Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Gln Gln 
1               5                   10                  15      
Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu 
            20                  25                  30          
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly 
        35                  40                  45              
Lys Pro Gln Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu 
    50                  55                  60                  
Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly 
65                  70                  75                  80  
Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser 
                85                  90                  95      
Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro 
            100                 105                 110         
Pro Arg 
        

